Gastric Inhibitory Polypeptide clinical trials
Also written GIP.
Its developmentBy Novo Nordisk, step by step1 company-led study, furthest phase 1: when each phase was reached, its deals, target and what is ahead.How each study uses Gastric Inhibitory Polypeptide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Gastric Inhibitory Polypeptide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 16
University Hospital, Gentofte, Copenhagen (3) · Asger Lund, MD (2) · Steno Diabetes Center Copenhagen (2) · David D'Alessio, M.D. (1) · Washington University School of Medicine (1) · University of Nottingham (1) · Rigshospitalet, Denmark (1) · National Institute on Aging (NIA) (1)
Often tested with
Tested in the same studies.
Glucagon-Like Peptide 1 (7) · Alanine (2) · Semaglutide (2) · Incretins (1) · Glimepiride (1) · Xenin 25 (1) · Insulin, Regular, Human (1) · Amino Acids (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Gastric Inhibitory Polypeptide.
- Dec 2026Beta-cell Response to Incretin Hormones in Cystic FibrosisNot applicable · University of Pennsylvania
- Jan 2027A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObesePhase 1 · Novo Nordisk A/S
- Mar 2027Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 InfusionNot applicable · Copenhagen University Hospital, Rigshospitalet
Studies
Open first, then newest update. How each study uses Gastric Inhibitory Polypeptide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 InfusionRecruitingNot applicableCopenhagen University Hospital, RigshospitaletNCT07398300Written as GIPHow we know
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseRecruitingPhase 1Novo Nordisk A/SNCT07411560Written as Glucose-dependent Insulinotropic Polypeptide (GIP)How we know
- Beta-cell Response to Incretin Hormones in Cystic FibrosisRecruitingNot applicableUniversity of PennsylvaniaNCT01851694Written as GIPHow we know
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT00992901Written as GLP-1 and GIPHow we know
- The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy IndividualsRecruitingPhase 1University Hospital, Gentofte, CopenhagenNCT06419686Written as GIPHow we know
- Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueRecruitingPhase 1/2Dr Adnan AghaNCT05751720Written as GIP/GLP-1aHow we know
- The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 DiabetesCompletedNot applicableAsger Lund, MDNCT06881472Written as Glucose-dependent Insulinotropic Polypeptide (GIP)How we know
- The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 DiabetesCompletedNot applicableAsger Lund, MDNCT05078255Written as Glucose-dependent insulinotropic polypeptide (GIP)How we know
- Incretin Action in Physiology and DiabetesCompletedPhase 1David D'Alessio, M.D.NCT02550548Written as GIP infusionHow we know
- Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT03556098Written as glucose-dependent insulinotropic peptideHow we know
- The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT03734718Written as GIPHow we know
- The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without SulphonylureaCompletedNot applicableUniversity Hospital, Gentofte, CopenhagenNCT03081676Written as Glucose-Dependent Insulinotropic PolypeptideHow we know
- The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin SecretionCompletedPhase 1Washington University School of MedicineNCT01951729Written as GIP with atropineHow we know
- Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal MuscleCompletedNot applicableUniversity of NottinghamNCT02370745Written as GIPHow we know
- Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?CompletedPhase 1/2University Hospital, Gentofte, CopenhagenNCT01048268Written as glucose-dependent insulinotropic polypeptideHow we know
- Hyperglycemia and the Extra-pancreatic Effect of IncretinsCompletedNot applicableRigshospitalet, DenmarkNCT01749163Written as GIPHow we know
- GIP: Glucose-dependent Insulinotropic PeptideCompletedPhase 1National Institute on Aging (NIA)NCT00239707Written as GIPHow we know
Given beside what is tested · 2 — Gastric Inhibitory Polypeptide is usual care or a partner of the new treatment
- Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes MellitusCompletedPhase 1Washington University School of MedicineNCT00798915Written as Glucose-dependent Insulinotropic Polypeptide (GIP)How we know
- Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell FunctionCompletedPhase 1Washington University School of MedicineNCT00949663Written as Glucose-dependent Insulinotropic Polypeptide (GIP)How we know
Codes
What other systems call Gastric Inhibitory Polypeptide · ClinicalTrials.gg INT007544
- MeSH (NLM) D005749Gastric Inhibitory PolypeptideOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005749 | Gastric Inhibitory Polypeptide | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.